Aims: Sodium glucose co-transporter 2 inhibitors (SGLT2i) are indicated for treatment of type 2 diabetes mellitus (T2DM); some SGLT2i have reported cardiovascular benefit, and some have reported risk of below-knee lower extremity (BKLE) amputation. This study examined the realworld comparative effectiveness within the SGLT2i class and compared with non-SGLT2i antihyperglycaemic agents. 
| INTRODUCTION
Canagliflozin is a sodium glucose co-transporter 2 inhibitor (SGLT2i) that is approved for the treatment of type 2 diabetes mellitus (T2DM).
In the CANagliflozin cardioVascular Assessment Study (CANVAS) Program that enrolled patients with T2DM and established cardiovascular disease or high cardiovascular risk, canagliflozin reduced the risk of major adverse cardiovascular events, hospitalization for heart failure (HHF) and death from cardiovascular causes or HHF relative to placebo, while increasing the risk of below-knee lower extremity (BKLE) amputation. 1 Multivariable analyses showed that the risk of amputation with canagliflozin was largely driven by known risk factors for amputation (ie, prior amputation, peripheral vascular disease, male sex, neuropathy, HbA1c > 8.0% and presence of cardiovascular disease), although canagliflozin treatment increased the risk of amputation independent of other risk factors. 2 The EMPA-REG OUTCOME trial showed a reduction in the risk of major adverse cardiovascular events, HHF and all-cause mortality with empagliflozin vs placebo; there was no report of an increased risk of amputation with empagliflozin. 3, 4 Findings from observational studies have confirmed the observed benefits of SGLT2i on HHF in clinical trials. 5, 6 Two retrospective database studies compared the risk of amputation with SGLT2i and non-SGLT2i. No difference in rate of amputation was seen among all new users in a privately insured, general population with T2DM, 21% with established cardiovascular disease, 7 while an increased risk was seen in a subpopulation of patients with T2DM and established cardiovascular disease in the Department of Defense Military Health System according to the EASEL study. 8 No study has directly compared drugs in the SGLT2i class to determine if there is a class effect for safety and effectiveness.
This study, OBSERVE-4D, examined the comparative effects of canagliflozin vs other SGLT2i and non-SGLT2i antihyperglycaemic agents (AHAs) on the risk of HHF and BKLE amputation in patients with T2DM, overall and within the subpopulation of patients with established cardiovascular disease, across 4 US administrative claims databases.
| MATERIALS AND METHODS
A series of analyses was conducted within this population-level effect estimation study following a retrospective comparative cohort design across 4 observational databases. The study was registered on ClinicalTrials.gov (NCT03492580), and the protocol was reviewed by the FDA prior to study execution. All analyses were pre-planned, with primary and sensitivity analyses pre-specified as part of the protocol; no post hoc sensitivity analyses were performed. The full protocol, including all diagnoses, procedures and drug codes used to define the cohorts, as well as all analytic source codes to execute the study, has been made publicly available at https://github.com/OHDSI/StudyProtocols/tree/master/ AhasHfBkleAmputation. 
| Data sources

| Exposure Cohorts
Six primary exposure cohorts of interest were defined as new users of: (1) 
| Outcome ascertainment
This study examined 2 primary outcomes of interest: (1) HHF and (2) BKLE amputation events. HHF was defined as all hospital admissions with a primary diagnosis of heart failure, as identified by ICD-9-CM and ICD-10-CM codes. BKLE amputation events were defined as all new BKLE amputation procedures, as identified by CPT-4 or ICD-9-PCS codes for amputation of lower leg, ankle, foot or toe, excluding recent (within 30 days) revisions.
Additionally, 44 negative control outcomes, that is, conditions believed not to be causally associated with any of the exposure cohorts based on product labeling, published literature and spontaneous adverse event reporting, which have been used in prior observational studies of canagliflozin, 7 were selected as a statistical diagnostic strategy to identify residual systematic error in the databases or study design and to empirically calibrate P values for any systematic error observed. 9, 10 For each negative control outcome, we assumed a priori that the true hazard ratio (HR) was 1, and we applied the same analysis designed for the outcomes of interest to each negative control outcome, with the difference between the estimated HR of the negative control and 1 representing an estimate of the systematic error present for that outcome. Using these error estimates from all 44 negative controls, we produced an empirical null distribution that reflects the range of potential bias that may be present within the unknown outcomes (eg, HHF and BKLE amputation) and used this distribution to compute a calibrated P value for each outcome.
| Time-at-risk periods
Two primary time-at-risk periods were evaluated: (1) an on-treatment period aimed at evaluating risk during the period in which an individual is exposed to the drug; and (2) an intent-to-treat period aimed at evaluating overall risk after initiating treatment. The on-treatment period was defined as the time from 1 day after exposure cohort start date (ie, the date of first exposure to the cohort-defining drug/s) until the exposure cohort end date, defined as the end of the first persistent period of exposure, allowing for a 30-day gap between successive exposures until the final exposure record. This exposure cohort end date represents the date the patient was expected to finish the dispensed supply of the last drug dispensed, but censoring at the time that any dispensing of a different non-metformin AHA was observed.
The intent-to-treat period was defined as the time from 1 day after exposure cohort start date to the end of the patient's observation period. Four additional time-at-risk variants were run for sensitivity analyses, as defined in the protocol.
| Statistical analyses
Crude incidence rates of both outcomes were estimated within each exposure cohort and pre-defined subgroups were estimated as the number of individuals with the outcome during each time-at-risk window, divided by the total time-at-risk.
Population-level effect estimation analyses using a comparative cohort design were applied for 7 pairwise comparisons and all associ- (1) time-to-first-post-index-event analysis, where hazards of an occurrence of outcome among all exposed patients were estimated, independent of prior outcome history; and (2) time-to-first-ever-event analysis, where hazards of first occurrence of outcome were estimated among patients with no history of the outcome.
Propensity score adjustment was used as an analytic strategy to reduce potential confounding as the result of imbalance between the target and comparator cohorts in baseline covariates. The propensity score is the probability of a patient being classified in the target cohort vs the comparator cohort, given a set of observed covariates.
The propensity score was estimated using the predicted probability from a regularized logistic regression model, fit with a Laplace prior (LASSO) and the regularization hyperparameter selected through For each outcome model, we reported the HR, 95% confidence interval (CI), nominal P value and empirically calibrated P value.
Standardized mean difference was used as a metric to evaluate the performance of propensity score adjustment. The propensity score distribution of the target and comparator cohorts was plotted to evaluate comparability of the 2 cohorts, scaling the plot to the preference score to normalize for any imbalance in cohort size. The potential for residual systematic error was examined by plotting the distribution of estimates from negative control outcomes.
A large set of sensitivity analyses was performed to evaluate the robustness of findings, the complete details of which are described in the protocol. For each pairwise comparison of target and comparator exposures (n = 7), for each outcome (n = 2) and for each database first post-index event) by 2 propensity score adjustment strategies (variable ratio matching, stratification). In total, 10 752 effect estimates were produced.
Data source-specific effect estimates were generated separately for each comparison-outcome-analysis combination in the 4 different populations, each of which reflects different patient compositions and follow-up times and could potentially reveal different effects. Additionally, random-effects meta-analytic estimates were generated using the DerSimonian-Laird and Hartung-Knapp-Sidik-Jonkman methods 13 to pool evidence across the 4 databases for all comparison-outcome-analyses for which there was sufficient homogeneity (I 2 < 40%). The meta-analytic estimates provide a composite summary which can serve as a useful supplement to the source-specific estimates that can have greater precision than any source-specific estimate. 14 Although our analysis should be considered a form of individual patient-level meta-analysis, we did not perform a "one-step" analysis because of the fundamental differences in populations. In order to preserve the internal validity of each population, we fit a propensity score model for each database that was unique to the patient composition and baseline characteristics of that database, and produced an effect estimate within the follow-up time provided by each source. We specified a priori that we would not produce a meta-analytic estimate when substantial heterogeneity was observed, because the variability reflects a potential violation of the random-effects assumption that study estimates were drawn from the same underlying effect distribution and the use of a composite summary could be inappropriate. 15 
| RESULTS
All results have been made publicly available through an interactive web-based application at http://data.ohdsi.org/AhasHfBkleAmputation.
This section summarizes the key findings across these results. person-years in the intent-to-treat analysis. Across all cohorts, MDCD had the highest incidence rates for BKLE amputation, while MDCD and MDCR had higher rates of HHF than CCAE and Optum. .65
| Overall population
. Time-to-first-post-index-event analysis using variable-ratio propensity score matching. Time-to-first-post-index-event analysis using variable-ratio propensity score matching. shorter follow-up time (median, 60-100 days on-treatment). Therefore, the current study had limited statistical power to detect differences in the 6 to 12-month period, the time at which amputation risk began to emerge in the CANVAS Program, particularly in patients with established cardiovascular disease. This discrepancy may be a limitation, as a constant risk assumption may be violated and the potential effect may require additional observation time before being detectable in a manner that is in line with the trial. On the other hand, it may be revealing that real-world utilization of these drugs suggests that the continuous exposure periods observed in clinical practice are often shorter than the point at which the purported risk may take effect. It is also possible that differences in the risk of BKLE amputation could be attributable to the composition of the patient population, as patients who opt to participate in clinical trials may not always reflect the general population. When attempting to reconcile these results with those of the EASEL study, it is worth highlighting that the EASEL population was older than that of CCAE, Optum and MDCD, and the EASEL study had a slightly longer median follow-up time. This study is subject to the limitations typical of observational database research, including the potential for unmeasured confounding and misclassification error that could bias the findings; however, the use of negative controls suggests little to no systematic error.
| Sensitivity analyses
Because the results were largely consistent across 4 databases, any such source of systematic error could be attributable to artifacts associated with the administrative claims process or consistent provider channeling behaviour that would persist independent of insurance coverage. No source record validation was performed to validate exposures, outcomes or baseline covariates, and it is possible that differential bias may have affected these attributes.
In this large observational study, treatment with canagliflozin was associated with lower risk of HHF than non-SGLT2i, and the risk of HHF with canagliflozin was comparable to that with other SGLT2i.
There were no observed differences in risk of BKLE amputation 
